Clinical trials: Liver Diseases, Alcoholic
Fatty Liver, Nonalcoholic, Diet, Healthy
Nutritional Education Program for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Study Summary Title: Mediterranean Diet Intervention for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial (The TIMA Study) Introduction: This trial, known as the TIMA (Taiwanese…
- Trial name
- TIMA (NCT06503120)
- Testing
- Mediterranean-diet intervention group, Standard care
- Where
- Taiwan
- Volunteers
- 78 people
- Sponsor
- Taichung Veterans General Hospital
Fatty Liver, Nutritional and Metabolic Disease
Low GI Diet Effects on Non-Alcoholic Fatty Liver Disease
A 2 x 2 cross-over dietary intervention trial designed to investigate the effects of low glycemic index (LGI) versus high glycemic index (HGI) diet on hepatic fat accumulation and gut microbiota composition in participants with…
- Trial name
- LGI-NAFLD (NCT04415632)
- Testing
- low glycemic index diet, High glycemic index diet
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Nottingham
Nonalcoholic Steatohepatitis
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with NASH and bridging (F3) fibrosis.
- Trial name
- STELLAR-3 (NCT03053050)
- Testing
- SEL
- Where
- 298 sites in United States, Argentina and 25 more
- Volunteers
- 808 people
- Sponsor
- Gilead Sciences
Non-alcoholic Fatty Liver Disease in Women With PCOS
Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)
This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS.
- Trial name
- NCT03617263
- Testing
- Saroglitazar Magnesium 4 mg Tablet
- Where
- 19 sites in United States, Mexico
- Volunteers
- 60 people
- Sponsor
- Zydus Therapeutics Inc.
NON-ALCOHOLIC STEATOHEPATITIS
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subjects with presumed non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT06054815
- Testing
- DA-1241, Sitagliptin
- Where
- 18 sites in United States
- Volunteers
- 109 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
NAFLD
Lifestyle Modification in the Treatment of NAFLD.
The project will study the impact of individually tailored lifestyle counselling compared to standard care on the parameters of NAFLD/NASH in patients with metabolic syndrome.
- Trial name
- NCT05816915
- Testing
- Cognitive behavioral therapy
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- General University Hospital, Prague
Non-Alcoholic Fatty Liver Disease, Immune Response
The Role of Immune Semaphorins in NAFLD
To goal is to identify semaphorins that are associated with NAFLD and to investigate their relationship with variable degrees of steatosis and fibrosis.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Immune Response, Biomarkers, Liver Fibrosis
- Trial name
- SepsisFAT (NCT04573543)
- Testing
- Evaluation of the degree of fibrosis and steatosis, Screening for the components of metabolic syndrome, Measurement of serum semaphorin concentrations
- Where
- Croatia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University Hospital for Infectious Diseases, Croatia
Non Alcoholic Steatohepatitis, Fibrosis
Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
This is a randomized, placebo-controlled phase 1/2a study to investigate the safety and tolerability of Idebenone in patients 18 years of age or older with non-alcoholic steatohepatitis, with stage 1-3 fibrosis.
- Trial name
- NCT04669158
- Testing
- Idebenone
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Stanford University
Nonalcoholic Steatohepatitis
Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis
This is a multi-center, randomized, placebo-controlled, double-blind, dose-selection, multiple dose administration study comprising three groups, with up to 40 patients in each active treatment and placebo group.
- Trial name
- NCT01466894
- Testing
- IMM 124-E
- Sponsor
- Immuron Ltd.
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease.
- Trial name
- NCT03938246
- Testing
- TVB-2640 25 mg (US), TVB-2640 50 mg (US), TVB-2640 50 mg (China)
- Where
- 23 sites in United States, China
- Volunteers
- 142 people
- Sponsor
- Sagimet Biosciences Inc.
Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
The effects of empagliflozin treatment on hepatocellular lipid content, liver energy metabolism and body composition will be investigated in a multicentre, prospective, placebo-controlled, double-blind, randomized, 2-arm…
- Trial name
- EmLiFa (NCT02637973)
- Testing
- Empagliflozin
- Where
- 5 sites in Germany
- Volunteers
- 84 people
- Sponsor
- The Deutsche Diabetes Forschungsgesellschaft e.V.
Non Alcoholic Fatty Liver Disease (NAFLD)
Potential Role of n-3 Fatty Acids in the Treatment of NAFLD in Pediatric Patients
Nonalcoholic hepatic steatosis (NASH) is defined as the amount greater than 5% of the total liver volume fat. Commonly known as NASH, it includes 4 stages histological ranging from the mere presence of fat to the existence of…
- Trial name
- NCT02201160
- Testing
- omega 3
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- St. Justine's Hospital
NAFLD
Diet and Physical Activity on NAFLD and Erytrocyte Membrane Lipid Profile.
This study aims to evaluate the effect of two programs of different intensity level of physical activity, of low glycemic index Mediterranean Diet and of the interaction of both, on NAFLD score and on the lipid composition of the…
- Trial name
- NCT02347696
- Testing
- Control, LGIMD, Endurance Activity (EA)
- Where
- Italy
- Volunteers
- 240 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Alcoholic Hepatitis, Alcoholic Cirrhosis
Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis
The study is aimed to evaluate the additional role of ciprofloxacin therapy in severe alcoholic hepatitis combined to prednisolone therapy in an open-label placebo controlled manner.
- Trial name
- NCT02326103
- Testing
- Ciprofloxacin
- Where
- Finland
- Volunteers
- 22 people
- Sponsor
- University of Helsinki
Non Alcoholic Fatty Liver Disease
UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
The purpose of this study is to assess UDFF performance (compared to MRI)
- Trial name
- UDFF (NCT06080386)
- Testing
- UDFF
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Fatty Liver, Nonalcoholic
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
Study question 1:Could SGLT2-I improve hepatic fibrosis, steatosis, and inflammatory markers in type 2 diabetic patients with Metabolic associated steatotic liver disease Question 2:Which drug of SGLT2-I group is more effective…
- Trial name
- NCT06117137
- Testing
- SGLT2 inhibitor
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Sohag University
Type 2 Diabetes (T2D)
Liver and Metabolic Effects of Insulin Pump Therapy in Diabetics Type 2 with Non-alcoholic Hepatic Steatosis
The prevalence of fatty liver disease (NAFLD: Non-Alcoholic Fatty Liver Disease or to a more severe degree NASH: Non-Alcoholic SteatoHepatitis) reached 40-70% in subjects with type 2 diabetes (T2D).
- Trial name
- STEATO-POMPE (NCT04270656)
- Testing
- Insulin pump therapy, Multi-injection treatment ( MDI ).
- Where
- 9 sites in France
- Volunteers
- 46 people
- Sponsor
- Nantes University Hospital
Alcoholic Hepatitis, Alcoholic Cirrhosis
Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment
The purpose of this study is to validate a strategy of identification of patients for early liver transplantation in severe alcoholic hepatitis. In this setting, short-term survival is very low (approx.
- Trial name
- QuickTrans (NCT01756794)
- Testing
- Liver transplantation
- Where
- 32 sites in Belgium, France
- Volunteers
- 284 people
- Sponsor
- University Hospital, Lille
Liver Diseases, Blood Disorder
NASH Fitness Intervention in Thrombosis Trial (NASHFit)
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the United States. The most advanced forms of NAFLD are associated with increased liver-related mortality and lower overall survival.
- Conditions
- Liver Diseases, Blood Disorder, Digestive System Disease
- Trial name
- NCT03518294
- Testing
- Aerobic Exercise
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Milton S. Hershey Medical Center
Alcoholic Hepatitis
Short-term Survival in Patients With Severe Alcoholic Hepatitis Treated With Steroid Versus Pentoxifylline
Alcoholic hepatitis represents one of the more serious forms of alcoholic liver disease. Critically ill patients with alcoholic hepatitis have high morbidity and mortality rate.
- Trial name
- NCT01455337
- Testing
- pentoxifylline, Prednisolone
- Volunteers
- 126 people
- Sponsor
- Inje University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.